Oral Care Evaluation to Prevent Oral Mucositis in Estrogen Receptor‐Positive Metastatic Breast Cancer Patients Treated with Everolimus (Oral Care‐BC): A Randomized Controlled Phase III Trial

BACKGROUND: The incidence of oral mucositis (any grade) after everolimus treatment is 58% in the general population and 81% in Asian patients. This study hypothesized that professional oral care (POC) before everolimus treatment could reduce the incidence of everolimus‐induced oral mucositis. MATERI...

Descripción completa

Detalles Bibliográficos
Autores principales: Niikura, Naoki, Nakatukasa, Katsuhiko, Amemiya, Takeshi, Watanabe, Ken‐ichi, Hata, Hironobu, Kikawa, Yuichiro, Taniike, Naoki, Yamanaka, Takashi, Mitsunaga, Sachiyo, Nakagami, Kazuhiko, Adachi, Moriyasu, Kondo, Naoto, Shibuya, Yasuyuki, Hayashi, Naoki, Naito, Mariko, Kashiwabara, Kosuke, Yamashita, Toshinari, Umeda, Masahiro, Mukai, Hirofumi, Ota, Yoshihide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Breast Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011665/
https://www.ncbi.nlm.nih.gov/pubmed/32043762
http://dx.doi.org/10.1634/theoncologist.2019-0382

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011665/
https://www.ncbi.nlm.nih.gov/pubmed/32043762
http://dx.doi.org/10.1634/theoncologist.2019-0382

Ejemplares similares